ArticleNature communications2018
Supramolecular aptamer nano-constructs for receptor-mediated targeting and light-triggered release of chemotherapeutics into cancer cells.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 78 citations in OpenAlex.
- Autonomous Microrobots for Spatiotemporally Active Therapeutic Delivery and Controlled Release.Cyborg and bionic systems (Washington, D.C.) · 2026Review
- Review
- Enhancing drug delivery with supramolecular amphiphilic macrocycle nanoparticles: selective targeting of CDK4/6 inhibitor palbociclib to melanoma.Biomaterials science · 2024Article
- A massively parallel screening platform for converting aptamers into molecular switches.Nature communications · 2023Article
- Aptamer-engineered (nano)materials for theranostic applications.Theranostics · 2023Review
- Light responsive nucleic acid for biomedical application.Exploration (Beijing, China) · 2022Review
- Fluorescence DNA Switch for Highly Sensitive Detection of miRNA Amplified by Duplex-Specific Nuclease.Sensors (Basel, Switzerland) · 2022Article
- Aptamer Probes Labeled with Lanthanide-Doped Carbon Nanodots Permit Dual-Modal Fluorescence and Mass Cytometric Imaging.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- G-Quadruplex-Based Drug Delivery Systems for Cancer Therapy.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Improving Breast Cancer Treatment Specificity Using Aptamers Obtained by 3D Cell-SELEX.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Aptamers and antibodies: rivals or allies in cancer targeted therapy?Exploration of targeted anti-tumor therapy · 2021Review
- Conventional Nanosized Drug Delivery Systems for Cancer Applications.Advances in experimental medicine and biology · 2021Article
- Light: A Magical Tool for Controlled Drug Delivery.Advanced functional materials · 2020Article
- Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy.International journal of molecular sciences · 2020Review
- Nucleic acid-based drug delivery strategies.Journal of controlled release : official journal of the Controlled Release Society · 2020Review
- Molecular dynamics study of the recognition of ATP by nucleic acid aptamers.Nucleic acids research · 2020Article
- Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer.Pharmaceutics · 2019Review
- Static DNA Nanostructures For Cancer Theranostics: Recent Progress In Design And Applications.Nanotechnology, science and applications · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
Platforms for targeted drug-delivery must simultaneously exhibit serum stability, efficient directed cell internalization, and triggered drug release. Here, using lipid-mediated self-assembly of aptamers, we combine multiple structural motifs into a single nanoconstruct that targets hepatocyte growth factor receptor (cMet). The nanocarrier consists of lipidated versions of a cMet-binding aptamer and a separate lipidated GC-rich DNA hairpin motif loaded with intercalated doxorubicin. Multiple 2',6'-dimethylazobenzene moieties are incorporated into the doxorubicin-binding motif to trigger the release of the chemotherapeutics by photoisomerization. The lipidated DNA scaffolds self-assemble into spherical hybrid-nanoconstructs that specifically bind cMet. The combined features of the nanocarriers increase serum nuclease resistance, favor their import into cells presumably mediated by endocytosis, and allow selective photo-release of the chemotherapeutic into the targeted cells. cMet-expressing H1838 tumor cells specifically internalize drug-loaded nanoconstructs, and subsequent UV exposure enhances cell mortality. This modular approach thus paves the way for novel classes of powerful aptamer-based therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.